Brainomix e-Lung Allows Earlier Detection of Progressive Pulmonary Fibrosis, New Study Reveals

Results from a US multicenter examine introduced at CHEST present e-Lung might have sped up Progressive Pulmonary Fibrosis (PPF) analysis by as much as 21 months

CHICAGO and OXFORD, England, Oct. 20, 2025 /PRNewswire/ — Brainomix, a world chief and pioneer of AI-powered imaging instruments in lung fibrosis and stroke, presents new proof on the CHEST Annual Meeting this week in Chicago displaying its Brainomix 360 e-Lung know-how might have considerably accelerated the analysis of Progressive Pulmonary Fibrosis (PPF) in over half of sufferers by as much as virtually two years.

Patients with Interstitial Lung Diseases (ILD) can develop PPF which causes irreversible lung injury and results in early mortality. The key to one of the best consequence and survival for sufferers is early initiation of therapy. However, figuring out sufferers eligible for therapy primarily based on imaging may be difficult, even for consultants.

Brainomix e-Lung is an FDA-cleared, AI-powered imaging software program platform that mechanically identifies and quantifies abnormalities on CT lung scans enabling clinicians to extra simply establish modifications together with delicate deteriorations over a number of scan timepoints. Powered by novel, proprietary know-how, e-Lung has been clinically validated to quantify lung options related to ILD.

The outcomes introduced this week at CHEST – together with equally notable outcomes introduced not too long ago on the European Respiratory Society (ERS) Congress – stem from the REVISE PPF retrospective analysis examine carried out with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham, displaying:

• e-Lung might have supported an earlier analysis of PPF in 62% of sufferers and as much as 21 months earlier.
• e-Lung recognized CT development in 77% of sufferers deemed clinically secure.
• The earlier development recognized by e-Lung was clinically vital and was related to survival, emphasising the worth of earlier detection.
• e-Lung precisely recognized sufferers vulnerable to growing future PPF from a single baseline scan.
• e-Lung metrics on the primary affected person scan are strong, unbiased predictors of mortality.

Dr Teja Kulkarni, Associate Professor and Director of the ILD Program on the University of Alabama at Birmingham, mentioned: “AI-powered CT analysis has the potential to transform pulmonary fibrosis care. It can enhance early detection, precisely quantify disease, and track progression over time. The data we have shown for e-Lung is very promising, and the ability to objectively assess parenchymal changes to predict disease trajectory and treatment responses could really help us personalize treatment decisions and improve outcomes for patients living with pulmonary fibrosis.”

Professor Peter George, Consultant Pulmonologist on the Royal Brompton Hospital, UK and Brainomix Senior Medical Director, mentioned: “Early diagnosis of progressive pulmonary fibrosis is a key goal which is associated with improved patient outcomes. The evidence building around e-Lung points to a new tool that enables physicians and radiologists to more accurately identify subtle, but clinically meaningful disease progression on CT scans. Maximizing the data we can extract from routinely performed CT scans has the potential to identify progressive pulmonary fibrosis months and even years earlier than is currently possible; I look forward to seeing this scientific advancement translated into tangible benefits for patients ultimately improving their quality of life and long-term outcomes.”

The two e-Lung research might be introduced as a part of the CHEST Rapid Fire sessions on Tuesday, October 21^st in Area 3A from 10:20 – 11:05AMCDT:

• Identification of Radiological Progressive Pulmonary Fibrosis in Clinically Stable Patients Using e-Lung Quantitative CT Algorithm: Results from REVISE PPF US Multicentre Study – Presented by Dr Teja Kulkarni
• The e-Lung Weighted Reticular Vascular Score Identifies Patients at Risk of Future Progressive Pulmonary Fibrosis: Results from the REVISE PPF Study – Presented by Professor Peter George

Notes to Editors

About Brainomix

Brainomix specializes within the creation of AI-powered software program options to allow precision drugs for higher therapy selections in stroke and lung fibrosis. With origins as a spinout from the University of Oxford, Brainomix is an increasing commercial-stage firm with places of work within the UK, Ireland and the USA, and operations in additional than 20 international locations. A personal firm, backed by main healthtech traders, Brainomix has innovated award-winning imaging biomarkers and software program options which were clinically adopted in tons of of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, gives clinicians with probably the most complete stroke imaging answer, driving elevated therapy charges and enhancing practical independence for sufferers.

To study extra about Brainomix and its know-how go to www.brainomix.com, and comply with us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing Officer
[email protected]
T +44 (0)1865 582730

Media Enquiries

Charles Consultants
Sue Charles
[email protected]
M +44 (0)7968 726585

Photo – https://mma.prnewswire.com/media/2798455/e_Lung_in_Clinical_Setting.jpg
Logo – https://mma.prnewswire.com/media/1989193/5567378/Brainomix_Logo.jpg

SOURCE Brainomix